These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14984629)

  • 1. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?
    Stahl SM
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):113-6. PubMed ID: 14984629
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
    Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
    Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital.
    Patrick V; Schleifer SJ; Nurenberg JR; Gill KJ
    Psychiatr Serv; 2006 Jan; 57(1):21-3. PubMed ID: 16399958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia.
    Hazra M; Uchida H; Sproule B; Remington G; Suzuki T; Mamo DC
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):676-8. PubMed ID: 22176287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatrists' self-reported adherence to evidence-based prescribing practices in the treatment of schizophrenia.
    Young GJ; Mohr DC; Meterko M; Seibert MN; McGlynn G
    Psychiatr Serv; 2006 Jan; 57(1):130-2. PubMed ID: 16399975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.
    Latimer EA; Naidu A; Moodie EE; Clark RE; Malla AK; Tamblyn R; Wynant W
    Psychiatr Serv; 2014 Oct; 65(10):1210-7. PubMed ID: 24981557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group].
    Yoshio T
    Seishin Shinkeigaku Zasshi; 2012; 114(6):690-5. PubMed ID: 22844820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic drugs: can education change prescribing practices?
    Schroeder NH; Caffey EM; Lorei TW
    J Clin Psychiatry; 1979 Apr; 40(4):186-9. PubMed ID: 33970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Explicit versus implicit review to explore combination antipsychotic prescribing.
    Wheeler A
    J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study.
    Barbui C; Biancosino B; Esposito E; Marmai L; Donà S; Grassi L
    Int Clin Psychopharmacol; 2007 Jul; 22(4):221-5. PubMed ID: 17519645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribing for inpatients with schizophrenia: an international multi-center comparative study.
    Bitter I; Chou JC; Ungvari GS; Tang WK; Xiang Z; Iwanami A; Gaszner P
    Pharmacopsychiatry; 2003 Jul; 36(4):143-9. PubMed ID: 12905100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Measures to reduce high-dose multiple antipsychotics in Japan].
    Sukegawa T
    Seishin Shinkeigaku Zasshi; 2012; 114(6):696-701. PubMed ID: 22844821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study.
    Yoshimura R; Okamoto T; Nakamura J; Tateno M; Otsuka K; Takahashi H; Fujisawa D; Takamatsu T; Fujii S; Sato S; Inoue M; Sasaki H; Kuroki T; Shinfuku N
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):778-9. PubMed ID: 17109719
    [No Abstract]   [Full Text] [Related]  

  • 14. The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.
    Andersen SE; Johansson M; Manniche C
    Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):75-81. PubMed ID: 18346047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic polypharmacy: never say never, but never say always.
    Stahl SM
    Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
    [No Abstract]   [Full Text] [Related]  

  • 17. It is time to assess the role of organizational culture in nursing home prescribing patterns.
    Gruneir A; Lapane KL
    Arch Intern Med; 2008 Jan; 168(2):238-9; author reply 239. PubMed ID: 18227376
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing irrational antipsychotic polypharmacy prescribing.
    Ellenor GL
    Hosp Pharm; 1977 Aug; 12(8):369-71, 374-6. PubMed ID: 10314400
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethnic comparisons of antipsychotic use in schizophrenia.
    Wheeler A; Humberstone V; Robinson E
    Aust N Z J Psychiatry; 2008 Oct; 42(10):863-73. PubMed ID: 18777230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.